Alcobra’s Pipeline In A Pill Aims To Capture The ADHD Market And More
This article was originally published in The Pink Sheet Daily
Founded in 2008, Alcobra has ridden a wave of impressive data, a friendly reception on the public markets, and growing investor interest in its bid to capture the ADHD market. Now, as it nears the start of Phase III for metadoxine, its unrelenting focus is on execution.
You may also be interested in...
Israeli firm contends that secondary endpoints address factors that matter most to patients, clinicians and caregivers, even though its metadoxine failed on the primary efficacy measure.
Eye doctors furious over Genentech's decision to halt sales of Avastin to compounding pharmacies have succeeded in grabbing the company's attention. On Oct. 26, three of Genentech's top officers, CEO Arthur Levinson, Chief Medical Officer Hal Barron, and president of product development, Susan Desmond-Hellmann, traveled to Washington, D.C. to meet with two physician groups
Lilly will add a "black box" warning to the product label for Strattera to communicate information on reports of suicidal thoughts among children and adolescents treated with the attention deficit/hyperactivity disorder medication